Publications by authors named "H Grasemann"
Background: The aim of this study was to quantify mediators of neutrophilic inflammation within airway extracellular vesicles (EVs) of children treated for a cystic fibrosis (CF) pulmonary exacerbation (PEx).
Methods: EVs were isolated from stored sputum samples collected before and after antibiotic therapy for PEx between 2011 and 2013, and characterised by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Western blot analysis of EV protein extracts was used for EV canonical protein markers CD63, CD9 and flotillin-1 (FLOT1), as well as neutrophil elastase (NE), myeloperoxidase (MPO) and interleukin-8.
Cystic fibrosis (CF) airways are L-arginine deficient which may affect susceptibility to infection with certain pathogens. The potential impact of L-arginine supplementation on , a common CF airway pathogen, is unclear. This study investigated the effects of L-arginine on biofilm cultures, using the laboratory strain PAO1 and multi-drug resistant CF clinical isolates.
View Article and Find Full Text PDFArticle Synopsis
- Elevated inflammation markers in cystic fibrosis (CF) patients can hinder lung function recovery after exacerbations; the study aimed to see if oral prednisone could help patients who weren’t improving with antibiotics.
- A randomized trial with 173 CF patients tested the effectiveness of prednisone against a placebo after 7 days of antibiotic treatment, measuring recovery of lung function (FEV).
- The results showed no significant difference in lung function recovery between the prednisone group (50% recovery) and the placebo group (39%), suggesting prednisone does not provide additional benefits for these patients.*
Background: Short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is an innate defence protein that acts as an anti-microbial agent and regulates airway surface liquid volume through inhibition of the epithelial sodium channel (ENaC). SPLUNC1 levels were found to be reduced in airway secretions of adults with cystic fibrosis (CF). The potential of SPLUNC1 as a biomarker in children with CF is unknown.
View Article and Find Full Text PDFBackground: Electronic nose (eNose) technology can be used to characterize volatile organic compound (VOC) mixes in breath. While previous reports have shown that eNose can detect lung infections with pathogens such as (SA) in people with cystic fibrosis (CF), the clinical utility of eNose for longitudinally monitoring SA infection status is unknown.
Methods: In this longitudinal study, a cloud-connected eNose, the SpiroNose, was used for the breath profile analysis of children with CF at two stable visits and compared based on changes in SA infection status between visits.